Patents by Inventor Andrew SANTIAGO-FRANGOS

Andrew SANTIAGO-FRANGOS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240182988
    Abstract: The disclosure relates to engineered systems and methods for detecting target nucleic acid in a sample, which may be a complex mixture. The systems and methods may improve sensitivity of target nucleic acid detection by enhancing signal generation. For example, signal generation may be enhanced through programmable capture and concentration of the target nucleic acid using an engineered type III CRISPR complex. Various ancillary nucleases such as Can1, Can2, and NucC are identified and may be used for detection. For example, binding of the engineered type III CRISPR complex may produce products that activate the identified ancillary nucleases. Different activators trigger changes in the substrate specificity of these nucleases. The activated nucleases may be used to detect programmatic detection of the target nucleic in the sample. The systems and methods are shown to detect viral RNA directly from nasopharyngeal swab samples.
    Type: Application
    Filed: June 8, 2023
    Publication date: June 6, 2024
    Applicant: Montana State University
    Inventors: Blake A. WIEDENHEFT, Andrew SANTIAGO-FRANGOS, Anna A. NEMUDRAIA, Artem A. NEMUDRYI
  • Patent number: 11814689
    Abstract: The disclosure relates to engineered systems and methods for detecting target nucleic acid in a sample, which may be a complex mixture. The systems and methods may improve sensitivity of target nucleic acid detection by enhancing signal generation. For example, signal generation may be enhanced through programmable capture and concentration of the target nucleic acid using an engineered type III CRISPR complex. Various ancillary nucleases such as Can1, Can2, and NucC are identified and may be used for detection. For example, binding of the engineered type III CRISPR complex may produce products that activate the identified ancillary nucleases. Different activators trigger changes in the substrate specificity of these nucleases. The activated nucleases may be used to detect programmatic detection of the target nucleic in the sample. The systems and methods are shown to detect viral RNA directly from nasopharyngeal swab samples.
    Type: Grant
    Filed: July 21, 2022
    Date of Patent: November 14, 2023
    Assignee: MONTANA STATE UNIVERSITY
    Inventors: Blake A. Wiedenheft, Andrew Santiago-Frangos, Anna A. Nemudraia, Artem A. Nemudryi
  • Publication number: 20230053573
    Abstract: The disclosure relates to engineered systems and methods for detecting target nucleic acid in a sample, which may be a complex mixture. The systems and methods may improve sensitivity of target nucleic acid detection by enhancing signal generation. For example, signal generation may be enhanced through programmable capture and concentration of the target nucleic acid using an engineered type III CRISPR complex. Various ancillary nucleases such as Can1, Can2, and NucC are identified and may be used for detection. For example, binding of the engineered type III CRISPR complex may produce products that activate the identified ancillary nucleases. Different activators trigger changes in the substrate specificity of these nucleases. The activated nucleases may be used to detect programmatic detection of the target nucleic in the sample. The systems and methods are shown to detect viral RNA directly from nasopharyngeal swab samples.
    Type: Application
    Filed: July 21, 2022
    Publication date: February 23, 2023
    Inventors: Blake A. WIEDENHEFT, Andrew SANTIAGO-FRANGOS, Anna A. NEMUDRAIA, Artem A. NEMUDRYI
  • Publication number: 20230057482
    Abstract: The disclosure relates to an engineered type III CRISPR-Cas system for sensitive and sequence specific detection of nucleic acid in a sample. For example, the engineered type III CRISPR-Cas system may be implemented as an assay for testing SARS-CoV-2 virus (or other target nucleic acid in the sample) that can be performed quickly, such as in one hour or less. Nucleic acid recognition by type III systems may trigger Cas10-mediated nuclease activity and/or polymerase activity, which may generate pyrophosphates, protons and cyclic oligonucleotides. The nuclease activity and/or the one or more products of the Cas10-polymerase are detected using colorimetric, visible fluorometric, and/or instrumented fluorometric detection.
    Type: Application
    Filed: July 25, 2022
    Publication date: February 23, 2023
    Inventors: Blake A. WIEDENHEFT, Andrew SANTIAGO-FRANGOS, Anna A. NEMUDRAIA, Artem A. NEMUDRYI
  • Publication number: 20210332446
    Abstract: The disclosure relates to an engineered type III CRISPR-Cas system for sensitive and sequence specific detection of nucleic acid in a sample. For example, the engineered type III CRISPR-Cas system may be implemented as an assay for testing SARS-CoV-2 virus (or other target nucleic acid in the sample) that can be performed quickly, such as in one hour or less. Nucleic acid recognition by type III systems may trigger Cas10-mediated nuclease activity and/or polymerase activity, which may generate pyrophosphates, protons and cyclic oligonucleotides. The nuclease activity and/or the one or more products of the Cas10-polymerase are detected using colorimetric, visible fluorometric, and/or instrumented fluorometric detection.
    Type: Application
    Filed: April 26, 2021
    Publication date: October 28, 2021
    Applicant: MONTANA STATE UNIVERSITY
    Inventors: Blake A. WIEDENHEFT, Andrew SANTIAGO-FRANGOS, Anna A. NEMUDRAIA, Artem A. NEMUDRYI